Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Research & Development (2016 - 2025)

Integra Lifesciences Holdings' Research & Development history spans 17 years, with the latest figure at $24.8 million for Q4 2025.

  • For Q4 2025, Research & Development fell 20.57% year-over-year to $24.8 million; the TTM value through Dec 2025 reached $99.0 million, down 14.22%, while the annual FY2025 figure was $99.0 million, 14.22% down from the prior year.
  • Research & Development for Q4 2025 was $24.8 million at Integra Lifesciences Holdings, up from $22.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $31.2 million in Q4 2024 and bottomed at $20.1 million in Q2 2021.
  • The 5-year median for Research & Development is $25.7 million (2021), against an average of $25.6 million.
  • The largest annual shift saw Research & Development surged 34.81% in 2021 before it decreased 20.57% in 2025.
  • A 5-year view of Research & Development shows it stood at $24.7 million in 2021, then increased by 8.32% to $26.8 million in 2022, then fell by 9.33% to $24.3 million in 2023, then grew by 28.52% to $31.2 million in 2024, then fell by 20.57% to $24.8 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Research & Development are $24.8 million (Q4 2025), $22.5 million (Q3 2025), and $27.0 million (Q2 2025).